Jasper Therapeutics, Inc.

This early-stage trial is testing a new drug called briquilimab for adults with chronic spontaneous urticaria (CSU), a condition causing long-lasting, itchy hives. The main goals are to find a safe dose and see if it helps reduce symptoms in people whose hives are not controlled …

This study is checking the long-term safety and effectiveness of the drug briquilimab for people with chronic hives (urticaria). It is open to people who have already taken part in a previous Jasper Therapeutics trial for this condition. The main goal is to see how safe the drug …